Results 41 to 50 of about 10,485 (198)

Qualitative differences among teriparatide-based pharmaceuticals,Differenziale qualitativo tra prodotti a base di teriparatide

, 2021
L’osteoporosi è una malattia sistemica dell’apparato scheletrico, che colpisce in Italia circa 5 milioni di persone di cui circa l’80% sono donne in post menopausa con aumentato rischio di fratture sia vertebrali che non.
Rossini, M., Gonnelli, S, Rossini, M, Proli, E. M., De_Rosa, MM, Alvaro, R., Navarra, P, Pennini, A., Proli, E. M, Navarra, P., Dominguez, LJ, de Rosa, M. M., Pennini, A, Alvaro, R, Leogrande, L., Leogrande, L, Viapiana, O., Gonnelli, S., Viapiana, O, Dominguez, L. J.   +19 more
core   +1 more source

Proteolysis at the extracellular matrix interface: Molecular architects and regulators in health and disease

The FEBS Journal, EarlyView.
The extracellular matrix (ECM) is a dynamic scaffold that orchestrates tissue architecture and cellular communication. A critical but underexplored interplay between proteases and cluster of differentiation molecules (CD) governs ECM turnover and directs cell fate.
David Jurnečka, Matija Hrovatin, Bor Bokalj, Boris Turk   +3 more
wiley   +1 more source

An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis

Indian Journal of Endocrinology and Metabolism, 2015
Background: One year, prospective, observational study in an Indian subpopulation to assess back pain in patients with severe osteoporosis treated with teriparatide or antiresorptives in a clinical setting. Materials and Methods: One hundred and nineteen
Harvinder Chhabra, Rajesh Malhotra, Sunil Marwah, Bharat Dave, Kyoungah See, Simrat Sohal, Sirel Gurbuz   +6 more
doaj   +1 more source

Multiple Myeloma Case Developed During the Use of the Teriparatide

, 2022
Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide, is a class of anabolic therapy for treating severe osteoporosis. Although plasma cell dyscrasias are excluded among the known side effects of teriparatide treatment, their ...
Mustafa Ünübol, İrfan Yavaşoğlu, Zehra Erdemir, Ayşe İyiyapıcı Ünübol, Esra Ercan Aktekin, Engin Güney   +5 more
core   +1 more source

Bone health in adults with non‐ambulatory neuromuscular disorders: scoping review of risk factors, diagnosis and management

Internal Medicine Journal, EarlyView.
Abstract Background Non‐ambulatory adults have an increased risk of osteoporosis and fractures due to reduced weight‐bearing and diminished neuromuscular stimulation, resulting in substantial morbidity and mortality. Aims This scoping review aimed to systematically evaluate risk factors, diagnostic indicators and management strategies for optimising ...
Thomas Bailey, Carolyn Droste, John A. Eisman, Steven G. Faux, Arnagretta Hunter   +4 more
wiley   +1 more source

Teriparatide Treatment Following Osteoporotic Hip Fracture in a Male Patient with Multiple Sclerosis and Current Recommendations

, 2015
A 58-year-old male patient with a diagnosis of multiple sclerosis (MS) who had been operated due to a low-energy subtrochanteric femoral fracture was admitted in order to plan anti-osteoporotic treatment and rehabilitation at post-operative first week ...
Sibel Başaran, Rengin Güzel, İlke Coşkun Benlidayı, Tunay Sarpel   +3 more
core   +1 more source

Osteoporosis and Periodontitis: Two‐Way Epidemiological and Mechanistic Evidence

Journal of Periodontal Research, EarlyView.
This review investigates the main mechanistic pathways connecting local periodontitis to systemic osteoporosis. Seven interconnected mechanisms are identified. ABSTRACT Osteoporosis and periodontitis are highly prevalent, chronic inflammatory diseases that constitute a major global health burden.
Jia Chang, Geeta Madhuri Bhuvanagiri, Megan Dulkanchainun, Cunyu Wang   +3 more
wiley   +1 more source

Acute development of cortical porosity and endosteal naïve bone formation from the daily but not weekly short-term administration of PTH in rabbit. [PDF]

PLoS ONE, 2017
Teriparatide [human parathyroid hormone (1-34)], which exerts an anabolic effect on bone, is used for the treatment of osteoporosis in patients who are at a high risk for fracture.
Hiroshi Yamane, Aya Takakura, Yukari Shimadzu, Toshiyuki Kodama, Ji-Won Lee, Yukihiro Isogai, Toshinori Ishizuya, Ryoko Takao-Kawabata, Tadahiro Iimura   +8 more
doaj   +1 more source

Effect of Teriparatide on Bone Mineral Density and Trabecular Bone Score in Type 2 Diabetic Patients with Osteoporosis: A Retrospective Cohort Study

Medicina, 2022
The BMDs of the lumbar spine, whole femur, and femoral neck and TBS were measured. Change in BMD or TBS was defined as the BMD or TBS at follow-up, performed 1 year after baseline, minus baseline BMD or TBS.
Chihiro Munekawa, Yoshitaka Hashimoto, Noriyuki Kitagawa, Takafumi Osaka, Masahide Hamaguchi, Michiaki Fukui   +5 more
doaj   +1 more source

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

Oral Diseases, EarlyView.
ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park, Shihyun Kim, Seo‐Yeong An, Reuben H. Kim, Jongho Choi, Moon‐Young Kim   +5 more
wiley   +1 more source